Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
June 30, 1998
Primary Completion Date
July 31, 2000
Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL
liposomal interleukin-2
BIOLOGICAL
polyvalent melanoma vaccine
BIOLOGICAL
recombinant interferon alfa
Trial Locations (1)
10016
Kaplan Cancer Center, New York
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
NYU Langone Health
OTHER
NCT00004104 - Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | Biotech Hunter | Biotech Hunter